NCT04441099 - NBE-002 in Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 19, 2020

Primary Completion Date

August 14, 2023

Study Completion Date

August 14, 2023

Conditions

Advanced Solid TumorAdvanced CancerTriple Negative Breast Cancer

Interventions

DRUG

NBE-002

NBE-002 will be given intravenously on Day 1 of repeated 28-day cycles.

Trial Locations (3)

Sarah Cannon Research Institute - TN Oncology, Nashville

The University of Texas MD Anderson Cancer Center, Houston

NEXT Oncology, San Antonio